Skip to main content
SpringerLink
Log in

Ethical Considerations in Cell Therapy

  • Chapter
  • First Online:
Cell Therapy

  • 1653 Accesses

Abstract

This chapter focuses on the ethical issues concerning the cell therapies that are offered within regulatory frameworks, as well as the ethical issues raised by those offered outside of regulatory frameworks. A discussion of ethical challenges in cell therapy clinical trial design is included. The chapter concludes with ethical considerations pertaining to the procurement and use of pluripotent stem cells: human embryonic stem cells and induced pluripotent stem cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hilts, P. J. (2003). Protecting America’s health: The FDA, business, and one hundred years of regulation. Knopf.

    Google Scholar 

  2. US Food and Drug Administration. (2019). FDA history: Part I: The 1906 food and drugs act and its enforcement. https://www.fda.gov/about-fda/fdas-evolving-regulatory-powers/part-i-1906-food-and-drugs-act-and-its-enforcement. (Last updated 24 April 2019) Last accessed 6 Mar 2021.

  3. US Food and Drug Administration. (2020, July). Regulatory considerations for human cell, tissues, and cellular and tissue-based products: Minimal manipulation and homologous use, guidance for industry and FDA staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal. (Last updated 21 July 2020) Last accessed 6 Mar 2021.

  4. Turner, L. (2017). ClinicalTrials.gov, stem cells and ‘pay-to participate’ clinical studies. Regenerative Medicine, 12(6), 705–719.

    Article  CAS  Google Scholar 

  5. Knoepfler, P. (2021, February 28). Regenerative reads: Brain organoids, Clinicaltrials.gov change. The Niche: Knoepfler Lab Stem Cell Blog. https://ipscell.com/2021/02/regenerative-reads-brain-organoids-clinicaltrials-gov-change/. Last accessed 6 Mar 2021.

  6. US Food and Drug Administration. (2016, September 13). Part 15 hearing: Draft guidances relating to the regulation of human cells, tissues, or cellular or tissue-based products. pp. 106–107.

    Google Scholar 

  7. U.S. Stem Cell. (2018, May 9). U.S. Department of justice files lawsuit at request of FDA to stop U.S. stem cell clinic from performing autologous stem cell procedure: USRM will vigorously defend medical freedom of Americans. http://us-stemcell.com/doj-files-lawsuit-against-usstemcellclinic/. Last accessed 6 Mar 2021.

  8. Lerner, I. J. (1981). Laetrile: A lesson in cancer quackery. CA: A Cancer Journal for Clinicians, 31(2), 91–95.

    CAS  Google Scholar 

  9. Annas, G. J. (2007). Cancer and the constitution – Choice at life’s end. The New England Journal of Medicine, 357(4), 408–413.

    Google Scholar 

  10. Darrow, J., Sarpatwari, J., Ameet, A., Kesselheim, J., & Aaron, S. (2015). Practical, legal, and ethical issues in expanded access to investigational drugs. The New England Journal of Medicine, 372(3), 279–286.

    Article  CAS  Google Scholar 

  11. Riva, L., Campanozzi, L., Vitali, M., Ricci, G., & Tambone, V. (2019). Unproven stem cell therapies: Is it my right to try? Annali dell’Istituto Superiore di Sanità, 55(2), 179–185.

    PubMed  Google Scholar 

  12. U.S. Food and Drug Administration. (2018, May). Expanded access program report. https://www.fda.gov/media/119971/download. Last accessed 6 Mar 2021.

  13. Right to Try Act. https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try. (Current as of January 14, 2020). Last accessed 6 Mar 2021.

  14. Appelbaum, P. S., Roth, L. H., Lidz, C. W., Benson, P., et al. (1987). False hopes and best data: Consent to research and the therapeutic misconception. The Hastings Center Report, 17(2), 20–24.

    Article  CAS  Google Scholar 

  15. Joffe, S., & Fernandez, L. H. (2018). Federal right-to-try legislation – Threatening the FDA’s public health mission. The New England Journal of Medicine, 378(8), 695–697.

    Article  Google Scholar 

  16. Kuriyan, A. E., Albini, T. A., Townsend, J. H., Rodriguez, M., et al. (2017). Vision loss after intravitreal injection of autologous “stem cells” for AMD. The New England Journal of Medicine, 376(11), 1047–1053.

    Article  Google Scholar 

  17. Ansari, Z. A., Kuriyan, A. E., & Albini, T. A. (2017). Unproven stem cell therapy for macular degeneration. Oncotarget, 8(52), 90636–90637.

    Article  Google Scholar 

  18. US Food and Drug Administration. (2017, August 24). Warning letter to US stem cell clinic, LLC. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-stem-cell-clinic-llc-524470-08242017. Last accessed 6 Mar 2021.

  19. US Food and Drug Administration. (2017, August 28). Statement from FDA Commissioner Scott Gottlieb, M.D. On the FDA’s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and regenerative medicine. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573443.htm. Last accessed 6 Mar 2021.

  20. Wan, W., & McGinley, L. (2019, April 4). FDA, N.Y. attorney general take steps to police stem cell industry. Washington Post.

    Google Scholar 

  21. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663–676.

    Article  CAS  Google Scholar 

  22. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861–872.

    Article  CAS  Google Scholar 

  23. Konomi, K., Tobita, M., Kumura, K., & Sato, D. (2015). New Japanese initiatives on stem cell therapies. Cell Stem Cell, 16, 350–352.

    Article  CAS  Google Scholar 

  24. Cyranoski, D. (2019). Stem-cell therapy raises concerns. Independent researchers warn that approval is premature. Nature, 565, 544–545.

    Article  CAS  Google Scholar 

  25. Nagai, S. (2019). Flexible and expedited regulatory review processes for innovative medicines and regenerative medical products in the US, the EU, and Japan. International Journal of Molecular Sciences, 20(15), 3801.

    Google Scholar 

  26. Cyranoski, D. (2019). Stem cells 2 go: Japan has turned regenerative medicine into a regulatory free-for-all. Patients across the world could pay the price. Nature, 573, 482–485.

    Article  CAS  Google Scholar 

  27. Knoepfler, P. (2019, June 3). Groundbreaking defeat for US stem cell, fat stem cell clinic industry in federal court. The Niche: Knoepfler Lab Stem Cell Blog. https://ipscell.com/2019/06/groundbreaking-defeat-for-us-stem-cell-fat-stem-cell-clinic-industry-in-federal-court/. Last accessed 6 Mar 2021.

  28. Sipp, D., & Sleeboom-Faulkner, M. (2019). Downgrading of regulation in regenerative medicine. Science, 366, 644–647.

    Article  Google Scholar 

  29. Daley, G. Q., Insoo Hyun, I., Apperley, J. F., Barker, R. A., et al. (2016). Setting global standards for stem cell research and clinical translation: The 2016 ISSCR guidelines. Stem Cell Reports, 6, 787–797.

    Article  Google Scholar 

  30. U.S. Food and Drug Administration. (2017, January). 22 case studies where phase 2 and phase 3 trials had divergent results. https://www.fda.gov/about-fda/reports/22-case-studies-where-phase-2-and-phase-3-trials-had-divergent-results. Last accessed 6 Mar 2021.

  31. Hamburg, M. A., & Sharfstein, J. M. (2009). The FDA as a public health agency. The New England Journal of Medicine, 360(24), 2493–2495.

    Article  CAS  Google Scholar 

  32. Miyamoto, S. (2019). Stem-cell treatment: Japan responds. Nature, 569, 40.

    Article  CAS  Google Scholar 

  33. Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., et al. (2003). A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Annals of Neurology, 54, 403–414.

    Google Scholar 

  34. Barker, R. A., & TRANSNEURO consortium. (2019). Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease. Nature Medicine, 25, 1045–1053.

    Article  CAS  Google Scholar 

  35. Jonlin, E. C. (2015). The voices of the embryo donors. Trends in Molecular Medicine, 21(2), 55–57.

    Article  Google Scholar 

  36. Stein, R. (2011, April 15). Stem cells were God’s will says the first recipient of treatment. https://www.washingtonpost.com/national/stem-cells-were-gods-will-says-first-recipient-of-treatment/2011/04/14/AFxgKIjD_story.html. Last accessed 6 Mar 2021.

  37. Jonlin, E. C. (2015). Consent for pluripotent cell use for therapy. Current Stem Cell Reports, 1(2), 92–101.

    Article  Google Scholar 

  38. Gymrek, M., McGuire, A. L., Golan, D., Halperin, E., et al. (2013). Identifying personal genomes by surname inference. Science, 339, 321–324.

    Article  CAS  Google Scholar 

  39. Charo, A. (2006). Body of research – Ownership and use of human tissue. The New England Journal of Medicine, 355(15), 1517–1519.

    Article  CAS  Google Scholar 

  40. Skloot, R. (2010). The immortal life of Henrietta Lacks. Crown Publishing Group.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA

    Erica C. Jonlin

Authors
  1. Erica C. Jonlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erica C. Jonlin .

Editor information

Editors and Affiliations

  1. Texas Children’s Cancer Center, Center for Cell and Gene Therapy, Houston, TX, USA

    Adrian P. Gee

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jonlin, E.C. (2022). Ethical Considerations in Cell Therapy. In: Gee, A.P. (eds) Cell Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-75537-9_6

Download citation

Publish with us

Policies and ethics

Search

Navigation